Krystal Biotech doses first patient in Phase 1/2 trial of KB801 for neurotrophic keratitis

Krystal Biotech, Inc.

First patient dosed in Phase 1/2 EMERALD-1 trial of KB801, a redosable eye-drop gene therapy for neurotrophic keratitis.
Study enrolls up to 27 adults with Stage 2 or 3 NK; 2:1 randomized to KB801 or placebo twice weekly for 8 weeks.
Primary endpoint: safety/tolerability; secondary: complete durable corneal healing at week 8.
NK diagnosed claims in US rose 115% from ~31,000 (2020) to ~68,000 (2024), per claims data.
Investor call/webcast July 9 at 8:30am ET to discuss KB801 program and trial design.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.